A 2-week open, randomized, crossover study was conducted in epileptic patients on chronic therapy, who took either carbamazepine (CBZ) 200 or CBZ 400 mg tablets. The oral dose was 1200 or 1600 mg/day, according to individual needs. There was no difference in absorption or steady-state levels between the two preparations.
The new galenic preparation of CBZ will help the neurologist to reduce the number of tablets taken by severe epileptic patients, with no risk but only benefits for the subjects.
Get full access to this article
View all access options for this article.
References
1.
CereghinoJ J (1982) Carbamazepine: Relation of plasma concentration to seizure control. In: WoodburyD MPenryJ KPippengerC E (Ed.), Antiepileptic drugs, Second Edition, Raven Press, New York, p 507.
2.
Farghali-HassanAssaelBMBossiLGarattiniSGernaMGomeniRMorselliPL (1976) Carbamazepine pharmacokinetics in young, adult and pregnant rats. Relation to pharmacological effects. Archives Internationales de Pharmacodynamic et de Therapie220, 125.
3.
LevyR HPitlickW H (1982) Carbamazepine. Interactions with other drugs. In: WoodburyD MPenryJ KPippengerC E (Ed.), Antiepileptic drugs. Second Edition, Raven Press, New York, p 497.
4.
MonacoFRiccioAFantiniMBaruzziAMorselliP L (1979) A month-by-month long-term study on carbamazepine. Clinical, pharmacological and EEG evaluation. Journal of International Medical Research7, 152.
5.
MorselliP L (1975) Carbamazepine: Absorption, distribution and excretion. Advances in Neurology11, 279.
6.
MorselliP LBossiL (1982) Carbamazepine: Absorption, distribution and excretion. In: WoodburyD MPenryJ KPippengerC E (Ed.), Antiepileptic drugs, Second Edition, Raven Press, New York, p 465.
7.
PynnönenSFreyHSillanpääM (1980) The autoinduction of carbamazepine during long-term therapy. International journal of Clinical Pharmacology, Therapeutics and Toxicology18, 247.
